3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug
By
Kimberly Bonvissuto
Jun 11, 2021
Three members of a Food & Drug Administration advisory panel resigned this week over the agency’s controversial decision on Monday to approve a novel therapy for Alzheimer’s disease.